Approval for engineering and design changes to the uvar xtsphotopheresis system. the device, as modified, will be marketed under the trade nametherakos cellex photopheresis system, and is indicated for use in the ultraviolet-a(uva) irradiation, in the presence of the photoactive drug 8-methoxypsoralen (8-mop), ofextracorporeally circulating leukocyte-enriched blood, in the palliative treatment of the skinmanifestations of cutaneous t-cell lymphoma (ctcl), in persons who have not been responsive to other forms of treatment.